ASPS Stance on Gender Reassignment Surgery for Minors
The American Society of Plastic Surgeons (ASPS) recently released a position statement advising against gender reassignment surgeries for minors. This recommendation, aimed at its 11,000 members, suggests that surgeries related to chest, genital, and facial modifications should be delayed until individuals are at least 19 years old. Remarkably, ASPS is the first prominent U.S. medical group to take a stand against the push from transgender activists advocating for early surgeries, citing insufficient evidence.
The statement reflects ASPS’s August 2024 conclusion, which noted that the existing evidence concerning gender-related endocrine and surgical treatments is of low quality. Recent studies have raised serious concerns about the long-term effects and irreversible nature of these procedures for young individuals, who may be in particularly vulnerable developmental stages.
ASPS has also referenced evaluations from Europe, particularly the UK’s Department of Health and Social Care, which indicate limitations in the current research quality and potential complications associated with treatment.
Current evidence shows that many children with prepubescent gender dysphoria often experience a significant reduction in distress as they approach adulthood without medical intervention. For those whose gender dysphoria begins in adolescence, the long-term outcomes are less predictable, casting further doubt on the appropriateness of immediate surgical intervention. The report from the Department of Health and Human Services emphasizes the ethical challenges inherent in this uncertainty, advocating for a cautious approach when irreversible interventions carry known risks.
Moreover, ASPS pointed out the ongoing debate among transgender activists who champion “youth autonomy” even amidst questionable evidence quality. While autonomy is often highlighted as a reason for urgent care, the document notes that true autonomy involves the patient’s right to accept or decline treatments, rather than an obligation for physicians to act where evidence suggests risks may outweigh benefits.
The ASPS’s perspective has shifted since 2019, when the organization previously opposed state-level restrictions on gender transition. Back then, they supported plastic surgery as a beneficial adjustment for those experiencing gender dysphoria. However, in August 2024, they altered their stance to reflect growing concerns about the long-term outcomes of transitioning surgeries.
Despite this shift, ASPS maintains its opposition to criminalizing gender reassignment practices, advocating instead for professional self-regulation within the field.
The current position has drawn praise from HHS Secretary Robert F. Kennedy Jr., who commended ASPS for upholding scientific integrity against what he called the “overmedicalization lobby.” He believes their stand will help protect future generations from potentially harmful decisions.
Dr. Mehmet Oz also stated that future medical ethics discussions will likely view the treatment of minors for gender issues similarly to historical interventions like lobotomies. He applauded ASPS for resisting methods deemed unscientific and dangerous.
In contrast, some major medical organizations, like the World Professional Association for Transgender Health (WPATH), continue to endorse gender transition interventions for children, despite facing criticism and several scandals. Reports have emerged of key individuals within WPATH discussing sensitive issues with minors with a concerning lack of engagement and foresight.
The Biden administration supports WPATH’s guidelines, which have come under fire, especially following executive orders from President Trump, who labeled them as “junk science.” He mandated all government agencies to dismiss policies reliant on WPATH’s recommendations, expressing his belief that these approaches inflict harm on children.
Recently, a New York jury awarded $2 million to a detransitioner who alleged that doctors coerced her into undergoing a double mastectomy at the age of 16. This case highlights ongoing legal and ethical concerns surrounding the treatment of gender dysphoria among minors.
